molecules-logo

Journal Browser

Journal Browser

Special Issue "Radiolabeled Compounds for Diagnosis and Treatment of Cancer"

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Bioorganic Chemistry".

Deadline for manuscript submissions: 31 July 2020.

Special Issue Editor

Prof. Dr. Krishan Kumar
Website
Guest Editor
Associate Professor of Radiology, The Wright Center of Innovation in Biomedical Imaging, The Ohio State University, Columbus, United States
Interests: drug discovery and development; targeted peptides and proteins for diagnosis and treatment of cancer; bioconjugation chemistry; imaging pharmaceuticals; PET probes; radiochemistry and radiolabeling of biomolecules
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

Significant advances in the design and evaluation of novel radiopharmaceuticals in preclinical and clinical environments have allowed for wider adoption of imaging technologies, such as SPECT and PET, and treatment of various cancers. Numerous radiopharmaceuticals have become available commercially for various applications, and more are going through development and the regulatory approval process. These radiopharmaceuticals are critical to the diagnosis and staging of diseases as well as the selection of patients for various therapies and the monitoring of their outcomes.

The editorial team of Molecules is developing a Special Issue titled “Radiolabeled Compounds for Diagnosis and Treatment of Cancer”. This Special Issue will focus on all aspects of design, characterization, evaluation, and development of novel radiolabeled compounds for the diagnosis and treatment of cancer and the application of new radiochemistry and methodologies for the development of novel radiolabeled compounds.

Submissions—both original research papers and reviews—related to the areas mentioned above are cordially invited.

Prof. Krishan Kumar
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Radiopharmaceuticals
  • Imaging pharmaceuticals
  • Diagnosis of cancer
  • Treatment of cancer
  • Radiolabeled compounds
  • Preclinical
  • Radiochemistry
  • Radiolabeling
  • Methodologies

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Open AccessReview
Pyrazoles as Key Scaffolds for the Development of Fluorine-18-Labeled Radiotracers for Positron Emission Tomography (PET)
Molecules 2020, 25(7), 1722; https://doi.org/10.3390/molecules25071722 - 09 Apr 2020
Abstract
The need for increasingly personalized medicine solutions (precision medicine) and quality medical treatments, has led to a growing demand and research for image-guided therapeutic solutions. Positron emission tomography (PET) is a powerful imaging technique that can be established using complementary imaging systems and [...] Read more.
The need for increasingly personalized medicine solutions (precision medicine) and quality medical treatments, has led to a growing demand and research for image-guided therapeutic solutions. Positron emission tomography (PET) is a powerful imaging technique that can be established using complementary imaging systems and selective imaging agents—chemical probes or radiotracers—which are drugs labeled with a radionuclide, also called radiopharmaceuticals. PET has two complementary purposes: selective imaging for diagnosis and monitoring of disease progression and response to treatment. The development of selective imaging agents is a growing research area, with a high number of diverse drugs, labeled with different radionuclides, being reported nowadays. This review article is focused on the use of pyrazoles as suitable scaffolds for the development of 18F-labeled radiotracers for PET imaging. A brief introduction to PET and pyrazoles, as key scaffolds in medicinal chemistry, is presented, followed by a description of the most important [18F]pyrazole-derived radiotracers (PET tracers) that have been developed in the last 20 years for selective PET imaging, grouped according to their specific targets. Full article
(This article belongs to the Special Issue Radiolabeled Compounds for Diagnosis and Treatment of Cancer)
Show Figures

Graphical abstract

Back to TopTop